VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2021 | Tafasitamab for R/R DLBCL

Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, comments on the use of tafasitamab, a CD19-targeted monoclonal antibody, and immune checkpoint inhibitors for the treatment of patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter